BR0207990A - Compostos antinflamatórios de triazolopiridinas - Google Patents
Compostos antinflamatórios de triazolopiridinasInfo
- Publication number
- BR0207990A BR0207990A BR0207990-9A BR0207990A BR0207990A BR 0207990 A BR0207990 A BR 0207990A BR 0207990 A BR0207990 A BR 0207990A BR 0207990 A BR0207990 A BR 0207990A
- Authority
- BR
- Brazil
- Prior art keywords
- triazolopyridine
- alkyl
- nitrogen
- hydrogen
- inflammatory compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"COMPOSTOS ANTIINFLAMATóRIOS DE TRIAZOLOPIRIDINAS". A presente invenção refere-se a novas triazolopiridinas da fórmula I em que Het é um heterociclo de 5 membros opcionalmente substituído contendo um a dois heteroátomos selecionados dentre nitrogênio, enxofre e oxigênio, em que pelo menos um dos referidos átomos heteroátomos deve ser nitrogênio; R^ 2^ é selecionado do grupo que conste por hidrogênio, (C~ 1~C~ 6~)alquila ou outros substituintes adequados; R^ 3^ é selecionado do grupo que conste por hidrogênio, (C~ 1~C~ 6~;)alquila ou outros substituintes adequados; s é um número inteiro desde O até 5; a intermediários para a sua preparação, a composições farmacêuticas que as contêm e ao seu uso em medicina. Os compostos da presente invenção são inibidores potentes de cinases MAP, preferivelmente a cinase p38. Eles são úteis no tratamento de inflamação, osteoartrite, artrite reumatóide, câncer, reperfusão ou isquemia no derrame cerebral ou ataque cardíaco, doenças auto-imunes e outros distúrbios.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27484001P | 2001-03-09 | 2001-03-09 | |
PCT/IB2002/000424 WO2002072579A1 (en) | 2001-03-09 | 2002-02-08 | Triazolopyridines as anti-inflammatory agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0207990A true BR0207990A (pt) | 2004-04-27 |
Family
ID=23049813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0207990-9A BR0207990A (pt) | 2001-03-09 | 2002-02-08 | Compostos antinflamatórios de triazolopiridinas |
Country Status (37)
Country | Link |
---|---|
US (1) | US6696464B2 (pt) |
EP (1) | EP1370559B1 (pt) |
JP (1) | JP4130774B2 (pt) |
KR (1) | KR20030080087A (pt) |
CN (1) | CN1496366A (pt) |
AP (1) | AP2002002463A0 (pt) |
AR (1) | AR036152A1 (pt) |
AT (1) | ATE323701T1 (pt) |
BG (1) | BG108133A (pt) |
BR (1) | BR0207990A (pt) |
CA (1) | CA2440222C (pt) |
CR (1) | CR7013A (pt) |
CZ (1) | CZ20032185A3 (pt) |
DE (1) | DE60210755T2 (pt) |
DO (1) | DOP2002000353A (pt) |
EA (1) | EA200300864A1 (pt) |
EC (1) | ECSP034762A (pt) |
EE (1) | EE200300437A (pt) |
ES (1) | ES2260415T3 (pt) |
GT (1) | GT200200042A (pt) |
HR (1) | HRP20030719A2 (pt) |
HU (1) | HUP0303415A2 (pt) |
IL (1) | IL156567A0 (pt) |
IS (1) | IS6858A (pt) |
MA (1) | MA26991A1 (pt) |
MX (1) | MXPA03008144A (pt) |
NO (1) | NO20033969L (pt) |
NZ (1) | NZ526528A (pt) |
OA (1) | OA12552A (pt) |
PA (1) | PA8541001A1 (pt) |
PE (1) | PE20030010A1 (pt) |
PL (1) | PL363959A1 (pt) |
SK (1) | SK10272003A3 (pt) |
TN (1) | TNSN02022A1 (pt) |
UY (1) | UY27199A1 (pt) |
WO (1) | WO2002072579A1 (pt) |
ZA (1) | ZA200304983B (pt) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372206B1 (en) * | 1989-03-02 | 2002-04-16 | University Of Florida | Orally-administered interferon-TAU compositions and methods |
US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
EP1854798A3 (en) * | 2000-09-19 | 2007-11-28 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
US7087636B2 (en) * | 2001-12-19 | 2006-08-08 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function |
CA2474192C (en) | 2002-02-12 | 2011-06-21 | Smithkline Beecham Corporation | Nicotinamide derivates useful as p38 inhibitors |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
US7012143B2 (en) | 2002-08-30 | 2006-03-14 | Dombroski Mark A | Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
PA8579601A1 (es) * | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
US7037923B2 (en) | 2002-08-30 | 2006-05-02 | Pfizer, Inc. | Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
US7005523B2 (en) | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
US20040092547A1 (en) * | 2002-08-30 | 2004-05-13 | Pfizer Inc | Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
AU2003253188A1 (en) * | 2002-08-30 | 2004-03-19 | Pfizer Products Inc. | Novel processes and intermediates for preparing triazolo-pyridines |
US6949652B2 (en) | 2002-08-30 | 2005-09-27 | Pfizer, Inc. | Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine |
ATE334131T1 (de) | 2003-02-14 | 2006-08-15 | Pfizer Prod Inc | Triazolopyridine als entzündungshemmende verbindungen |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
AU2004218463B2 (en) | 2003-03-03 | 2009-07-16 | Array Biopharma, Inc. | p38 inhibitors and methods of use thereof |
PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
CA2550064A1 (en) * | 2003-12-18 | 2005-07-07 | Pfizer Products Inc. | Methods of treating acute inflammation in animals with p38 map kinase inhibitors |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
AU2005260031B2 (en) * | 2004-06-25 | 2008-10-09 | Amgen Inc. | Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases |
KR100871535B1 (ko) | 2004-08-12 | 2008-12-05 | 화이자 인코포레이티드 | P38 map 키나아제 억제제로서의트리아졸로피리딘일설판일 유도체 |
MX2007001759A (es) | 2004-08-12 | 2007-04-20 | Pfizer | Derivados de triazolopiridinilsulfanilo como inhbidores de proteina quinasa activada por mitogenos. |
MX2007002050A (es) * | 2004-08-18 | 2007-03-29 | Pharmacia & Upjohn Co Llc | Compuestos de triazolopiridina. |
US20090215817A1 (en) * | 2004-08-18 | 2009-08-27 | Pfizer Inc | Novel Triazolopyridine Compounds for the Treatment of Inflammation |
US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
US7579360B2 (en) * | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US7572807B2 (en) * | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
PE20070341A1 (es) * | 2005-07-29 | 2007-04-13 | Wyeth Corp | Derivados de pirrol como moduladores del receptor de progesterona |
PE20070182A1 (es) | 2005-07-29 | 2007-03-06 | Wyeth Corp | Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona |
PE20070404A1 (es) * | 2005-07-29 | 2007-05-10 | Wyeth Corp | Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona |
US8044083B2 (en) | 2006-01-31 | 2011-10-25 | Array Biopharma Inc. | Kinase inhibitors and methods of use thereof |
WO2008021781A1 (en) | 2006-08-07 | 2008-02-21 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
ES2301380B1 (es) | 2006-08-09 | 2009-06-08 | Laboratorios Almirall S.A. | Nuevos derivados de 1,7-naftiridina. |
WO2008063287A2 (en) | 2006-10-06 | 2008-05-29 | Abbott Laboratories | Novel imidazothiazoles and imidazoxazoles |
MY188335A (en) | 2006-11-22 | 2021-11-30 | Incyte Holdings Corp | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
ES2329639B1 (es) | 2007-04-26 | 2010-09-23 | Laboratorios Almirall S.A. | Nuevos derivados de 4,8-difenilpoliazanaftaleno. |
WO2009005675A1 (en) * | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
WO2009027283A1 (en) * | 2007-08-31 | 2009-03-05 | Merck Serono S.A. | Triazolopyridine compounds and their use as ask inhibitors |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
MX368802B (es) | 2008-05-21 | 2019-10-17 | Incyte Corp | Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1, 2-b][1 ,2, 4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas. |
US8895550B2 (en) | 2008-08-19 | 2014-11-25 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為pim激酶抑制劑之三唑吡啶化合物 |
WO2010022081A1 (en) | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
US8987251B2 (en) | 2008-08-19 | 2015-03-24 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
HUE034911T2 (hu) | 2009-07-27 | 2018-03-28 | Gilead Sciences Inc | Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok |
EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
CA2788398C (en) | 2010-02-03 | 2018-02-27 | Incyte Corporation | Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors |
ES2529119T3 (es) | 2010-07-02 | 2015-02-17 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de canales iónicos |
CN103370316B (zh) * | 2010-11-16 | 2015-06-24 | 南京英派药业有限公司 | 作为细胞增殖抑制剂的3-芳基-6-芳基-[1,2,4]三唑并[4,3-a]吡啶及其应用 |
WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
PL2678329T3 (pl) | 2011-02-25 | 2016-06-30 | Array Biopharma Inc | Związki triazolopirydyny jako inhibitory kinaz pim |
JP5934787B2 (ja) | 2011-05-10 | 2016-06-15 | ギリアード サイエンシーズ, インコーポレイテッド | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
NO3175985T3 (pt) | 2011-07-01 | 2018-04-28 | ||
EP2968280A4 (en) * | 2013-03-14 | 2016-08-10 | Genentech Inc | SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF |
GB201321742D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
US11479770B2 (en) | 2017-10-05 | 2022-10-25 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of DUX4 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN116514801A (zh) * | 2022-01-20 | 2023-08-01 | 四川大学 | 2-苯基-[1,2,4]三唑并[1,5-a]吡啶类化合物、其氮氧化物及用途 |
CN114504636B (zh) * | 2022-01-27 | 2023-09-26 | 华南理工大学 | 一种杏仁油烫伤膏及其制备方法与应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US576499A (en) * | 1897-02-02 | Gas apparatus | ||
US5716972A (en) * | 1993-01-13 | 1998-02-10 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
JP3377529B2 (ja) | 1993-09-17 | 2003-02-17 | スミスクライン・ビーチャム・コーポレイション | 薬物結合タンパク質 |
IT1269176B (it) * | 1994-01-11 | 1997-03-21 | Isagro Srl | Eterobicicli ad attivita' fungicida |
US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
ZA97175B (en) * | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
ES2205167T3 (es) | 1996-01-11 | 2004-05-01 | Smithkline Beecham Corporation | Nuevos compuestos de imidazol sustituidos. |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
CA2333157A1 (en) | 1998-05-26 | 1999-12-02 | Smithkline Beecham Corporation | Novel substituted imidazole compounds |
US6207687B1 (en) * | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
US6350744B1 (en) | 1998-11-20 | 2002-02-26 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
ATE227719T1 (de) | 1998-12-16 | 2002-11-15 | Aventis Pharma Ltd | Heteroaryl-zyklische acetale |
WO2000040243A1 (en) | 1999-01-08 | 2000-07-13 | Smithkline Beecham Corporation | Novel compounds |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
CO5170501A1 (es) | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
-
2002
- 2002-02-08 EP EP02710260A patent/EP1370559B1/en not_active Expired - Lifetime
- 2002-02-08 MX MXPA03008144A patent/MXPA03008144A/es active IP Right Grant
- 2002-02-08 EA EA200300864A patent/EA200300864A1/ru unknown
- 2002-02-08 AT AT02710260T patent/ATE323701T1/de not_active IP Right Cessation
- 2002-02-08 PL PL02363959A patent/PL363959A1/xx not_active Application Discontinuation
- 2002-02-08 DE DE60210755T patent/DE60210755T2/de not_active Expired - Fee Related
- 2002-02-08 AP APAP/P/2002/002463A patent/AP2002002463A0/en unknown
- 2002-02-08 CN CNA028062825A patent/CN1496366A/zh active Pending
- 2002-02-08 WO PCT/IB2002/000424 patent/WO2002072579A1/en active IP Right Grant
- 2002-02-08 ES ES02710260T patent/ES2260415T3/es not_active Expired - Lifetime
- 2002-02-08 JP JP2002571495A patent/JP4130774B2/ja not_active Expired - Fee Related
- 2002-02-08 BR BR0207990-9A patent/BR0207990A/pt not_active IP Right Cessation
- 2002-02-08 NZ NZ526528A patent/NZ526528A/en unknown
- 2002-02-08 SK SK1027-2003A patent/SK10272003A3/sk unknown
- 2002-02-08 CZ CZ20032185A patent/CZ20032185A3/cs unknown
- 2002-02-08 IL IL15656702A patent/IL156567A0/xx unknown
- 2002-02-08 HU HU0303415A patent/HUP0303415A2/hu unknown
- 2002-02-08 KR KR10-2003-7011919A patent/KR20030080087A/ko not_active Application Discontinuation
- 2002-02-08 OA OA1200300203A patent/OA12552A/en unknown
- 2002-02-08 CA CA002440222A patent/CA2440222C/en not_active Expired - Fee Related
- 2002-02-08 EE EEP200300437A patent/EE200300437A/xx unknown
- 2002-03-05 GT GT200200042A patent/GT200200042A/es unknown
- 2002-03-06 DO DO2002000353A patent/DOP2002000353A/es unknown
- 2002-03-07 PE PE2002000182A patent/PE20030010A1/es not_active Application Discontinuation
- 2002-03-07 AR ARP020100826A patent/AR036152A1/es unknown
- 2002-03-07 UY UY27199A patent/UY27199A1/es not_active Application Discontinuation
- 2002-03-08 TN TNTNSN02022A patent/TNSN02022A1/fr unknown
- 2002-03-08 PA PA20028541001A patent/PA8541001A1/es unknown
- 2002-03-11 US US10/094,760 patent/US6696464B2/en not_active Expired - Fee Related
-
2003
- 2003-06-23 IS IS6858A patent/IS6858A/is unknown
- 2003-06-26 ZA ZA200304983A patent/ZA200304983B/en unknown
- 2003-06-30 CR CR7013A patent/CR7013A/es not_active Application Discontinuation
- 2003-08-07 MA MA27269A patent/MA26991A1/fr unknown
- 2003-08-25 BG BG108133A patent/BG108133A/bg unknown
- 2003-09-08 NO NO20033969A patent/NO20033969L/no not_active Application Discontinuation
- 2003-09-09 HR HR20030719A patent/HRP20030719A2/hr not_active Application Discontinuation
- 2003-09-09 EC EC2003004762A patent/ECSP034762A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0207990A (pt) | Compostos antinflamatórios de triazolopiridinas | |
BR0207957A (pt) | Compostos antiinflamatórios de benzimidazol | |
BR0201087A (pt) | Compostos antiinflamatórios de benzotriazol | |
BR0014133A (pt) | Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
BR0110240A (pt) | Composto, processo para a preparação de um composto, processo para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
HUP0202703A2 (hu) | Poli(ADP-ribóz) polimerázok triciklusos inhibítorai és ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
BR9914379A (pt) | Composto, processo para a preparação de um composto, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
HUP0401083A2 (hu) | 4-Amino-6-fenil-pirrolo[2,3-d]pirimidin-származékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására | |
HUP0402310A2 (hu) | 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények | |
BR0111754A (pt) | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica | |
BR9914451A (pt) | Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento | |
BR0014136A (pt) | Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
ATE164575T1 (de) | Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer | |
AR035554A1 (es) | Compuesto derivado de indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de quinasa proteina. | |
CA2669680A1 (en) | Compounds for inhibiting mitotic progression | |
BR9908850A (pt) | Biciclo [2.2.1]|heptanos e compostos relacionados | |
ME00584A (en) | N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, preparation thereof and therapeutic use thereof | |
MXPA05008568A (es) | Nuevos compuestos anti-inflamatorios triazolo-piridinas. | |
HUP0401333A2 (hu) | Spiropirazol vegyületek és ezeket tartalmazó gyógyszerkészítmények | |
BR0312633A (pt) | Composto, uso do composto, composição farmacêutica, processo para a preparação de um composto | |
HUP0301032A2 (hu) | Ciklin-dependens kinázok N-{5-[(5-alkil-2-oxazolil)-metil-tio]-2-tiazolil}-karboxamid inhibitorai, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
BR0313961A (pt) | Processos e intermediários para preparar triazolo-piridinas | |
DE602004015108D1 (de) | (3-((chinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs | |
ES482788A1 (es) | Un procedimiento para preparar derivados de flavano monodi- y tri-sustituidos. | |
BRPI0407052A (pt) | Inibidores da hiv-integrase, composições farmacêuticas, e métodos para sua utilização |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A(S) 9A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011. |